Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the KIZ gene.
Features include always present findings: Perifoveal hypoautofluorescence, Nyctalopia, Pigmentary retinopathy, and Rod-cone dystrophy; and common findings: Constriction of peripheral visual field, Undetectable electroretinogram, and Reduced visual acuity.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Pigmentary retinopathy |
Age of onset: middle age.
KIZ encodes kizuna centrosomal protein (673 aa). Centrosomal protein required for establishing a robust mitotic centrosome architecture that can endure the forces that converge on the centrosomes during spindle formation. Highest expression in Colon Sigmoid (60.4 TPM) and Cervix Endocervix (50.2 TPM).
Retinitis pigmentosa 69 is associated with mutations in the KIZ gene on chromosome 20.
KIZ is classified as a druggable target with score 0.0.
Genetic testing for KIZ is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 69 has been reported in the published literature.
Phenotype severity distribution: 4 always present features, 3 common features.
No clinical trials have been registered for retinitis pigmentosa 69.
48 publications have been identified in PubMed for retinitis pigmentosa 69. Research spans Epidemiology / Natural History (44%), Basic Science / Preclinical (21%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 21 | 44% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:04 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Laboratory research
10 |
21% |
Testing and diagnosis research | 6 | 13% |
Research summaries | 4 | 8% |
Other research | 3 | 6% |
Clinical study results | 2 | 4% |
New treatment approaches | 2 | 4% |
Parekh BJ (2026). [PMID: 41760091](https://pubmed.ncbi.nlm.nih.gov/41760091/). *Clin Exp Ophthalmol*. [Epidemiology / Natural History]
Kong MD (2026). [PMID: 41557064](https://pubmed.ncbi.nlm.nih.gov/41557064/). *Doc Ophthalmol*. [Basic Science / Preclinical]
Na H (2026). [PMID: 42256003](https://pubmed.ncbi.nlm.nih.gov/42256003/). *Ophthalmol Sci*. [Basic Science / Preclinical]
Most JA (2026). [PMID: 40743462](https://pubmed.ncbi.nlm.nih.gov/40743462/). *Retina*. [Basic Science / Preclinical]
Jony MJ (2026). [PMID: 41944104](https://pubmed.ncbi.nlm.nih.gov/41944104/). *Curr Drug Deliv*. [Basic Science / Preclinical]
Martins PM (2026). [PMID: 41615371](https://pubmed.ncbi.nlm.nih.gov/41615371/). *Invest Ophthalmol Vis Sci*. [Basic Science / Preclinical]
Beaulieu C (2026). [PMID: 41954904](https://pubmed.ncbi.nlm.nih.gov/41954904/). *JAMA Ophthalmol*. [Epidemiology / Natural History]
Carpenter E (2026). [PMID: 41632744](https://pubmed.ncbi.nlm.nih.gov/41632744/). *Ophthalmic Res*. [Epidemiology / Natural History]
Yang P (2025). [PMID: 39643074](https://pubmed.ncbi.nlm.nih.gov/39643074/). *Am J Ophthalmol*. [Clinical Trial Publication]
Lähteenoja L (2025). [PMID: 40571344](https://pubmed.ncbi.nlm.nih.gov/40571344/). *Br J Ophthalmol*. [Epidemiology / Natural History]